Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

FDA Approves Brigatinib for ALK-Positive Metastatic NSCLC

FDA also approved the Vysis ALK Break Apart FISH Probe Kit as a companion diagnostic
28 May 2020
Anticancer agents & Biologic therapy;  Lung and other thoracic tumours;  Personalised medicine

On 22 May 2020, the US Food and Drug Administration (FDA) approved brigatinib (ALUNBRIG, ARIAD Pharmaceuticals Inc.) for adult patients with anaplastic lymphoma kinase (ALK)-positive metastatic non-small cell lung cancer (NSCLC) as detected by an FDA-approved test.

The FDA also approved the Vysis ALK Break Apart FISH Probe Kit (Abbott Molecular, Inc.) as a companion diagnostic for brigatinib.

Efficacy was investigated in ALTA 1L (NCT02737501), a randomised (1:1), open-label, multicentre trial in adult patients with advanced ALK-positive NSCLC who had not previously received an ALK-targeted therapy. The trial required patients to have an ALK rearrangement based on a local standard of care testing. The trial randomised 275 patients to receive brigatinib 180 mg orally once daily with a 7-day lead-in at 90 mg once daily (n=137) or crizotinib 250 mg orally twice daily (n=138). A subset of the clinical samples was retrospectively tested with the Vysis ALK Break Apart FISH Probe Kit. Of the enrolled patients, 239 had positive results using the Vysis diagnostic test (central results were negative for 20 patients and unavailable for 16 patients).

The major efficacy outcome measure was progression-free survival (PFS) evaluated by a blinded independent review committee according to RECIST v1.1. Additional efficacy outcome measures as evaluated by the blinded independent central review BIRC was confirmed overall response rate (ORR).

Estimated median PFS for patients treated with brigatinib was 24 months (95% confidence interval [CI] 18.5, NE) compared with 11 months (95% CI 9.2, 12.9) for those treated with crizotinib (hazard ratio [HR] 0.49; 95% CI 0.35, 0.68; p < 0.0001). Confirmed ORR was 74% (95% CI 66, 81) and 62% (95% CI 53, 70), respectively. 

The most common adverse reactions (≥25%) with brigatinib were diarrhoea, fatigue, nausea, rash, cough, myalgia, headache, hypertension, vomiting, and dyspnoea.

The recommended brigatinib dose is 90 mg orally once daily for the first 7 days; then increase to 180 mg orally once daily. Brigatinib may be taken with or without food.

Full prescribing information for ALUNBRIG is available here.

This review used the Assessment Ais, a voluntary submission from the applicant to facilitate the FDA’s assessment.

This application was granted priority review. Brigatinib also received orphan drug designation. 

Healthcare professionals should report all serious adverse events suspected to be associated with the use of any medicine and device to FDA’s MedWatch Reporting System.

For assistance with single-patient INDs for investigational oncology products, healthcare professionals may contact FDA’s Oncology Center of Excellence Project Facilitate. 

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings